RANDOMIZED, PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CONVENTIONALCHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS CEDIRANIB VERSUSCONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS PLACEBO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA